News

Biogen and Envisagenics Announce Collaboration to Advance RNA Splicing Research

As part of the agreement, Biogen will leverage Envisagenics’ AI platform with the goal of better understanding Central Nervous System diseases CAMBRIDGE, Mass. and NEW YORK, May 13, 2021 (GLOBE NEWSWIRE) -- Biogen Inc. (Nasdaq: BIIB) and Envisagenics today announced a new collaboration to advance

Biogen Announces Exercise of Option to Acquire the Investigational Drug TMS-007 for Acute Ischemic Stroke Based on Positive Phase 2a Data

TMS-007 has the potential to be a next generation thrombolytic with an improved benefit-risk profile Acute ischemic stroke is caused by a blockage of blood supply to the brain, and current thrombolytics are limited in use due in part to increased risks of bleeding Phase 2a study demonstrated

Biogen and Capsigen Announce Collaboration to Discover and Develop Novel AAV Capsids for Targeted CNS and Neuromuscular Disorders

Collaboration aims to identify novel AAV capsids with enhanced properties to facilitate the development of new gene therapies for CNS and neuromuscular disorders Capsigen’s screening technology is designed to produce dose optimized, fit for purpose vectors that may have applicability across

Biogen Provides Regulatory Update on the Supplemental Biologic License Application (sBLA) for Subcutaneous Administration of TYSABRI® (natalizumab)

CAMBRIDGE, Mass., April 28, 2021 (GLOBE NEWSWIRE) -- Biogen Inc. (Nasdaq: BIIB) today announced that it has received a Complete Response Letter (CRL) from the U.S. Food and Drug Administration (FDA) for its supplemental Biologic License Application (sBLA) for a new subcutaneous (SC) route of

Biogen Releases 2020 Year in Review Demonstrating Its Commitment to Transparency and Progress across Environmental, Social and Governance Metrics

Accelerated action on climate, health and equity, including new plastic-free packaging goals for finished goods by 2025 1 Disclosed 2020 global pay equity analysis results 2 and launched enhanced four-part diversity, equity and inclusion strategy Tied a portion of employees’ and executive officers’

Biogen Reports First Quarter 2021 Results

18-Month, Pre-Specified Analysis Showing Consistent Reduction in Clinical Outcome Measures from a Lecanemab (BAN2401) Phase 2b Clinical Trial in Early Alzheimer's Disease Published in Peer-Reviewed Journal, Alzheimer's Research and Therapy

Lecanemab Phase 3 Clarity AD Clinical Trial Completed Enrollment TOKYO , April 19, 2021 /PRNewswire/ -- Eisai Co., Ltd. (Headquarters: Tokyo , CEO: Haruo Naito , "Eisai") and Biogen Inc. (Nasdaq: BIIB, Corporate headquarters: Cambridge, Massachusetts , CEO: Michel Vounatsos , "Biogen") today

Biogen Advances Leading Research in Spinal Muscular Atrophy (SMA) with New Data at AAN 2021 Exploring Opportunities to Improve Outcomes for Patients

Initial findings from the DEVOTE study suggest no new safety concerns and support continued development of a higher dose of SPINRAZA ® (nusinersen) Additional research reinforces the potential of biomarkers and highlights new digital tools that may help guide future treatment approaches and

New Data at AAN 2021 from Across Biogen’s MS Portfolio Demonstrate Positive Impact of Treatment on People Living with Relapsing Multiple Sclerosis

New findings from MS PATHS show that treatment with TYSABRI ®  (natalizumab) can lead to meaningful improvements in mental and social health compared to Ocrevus ® (ocrelizumab) Real-world data from VUMERITY ® (diroximel fumarate) reinforce the treatment’s positive gastrointestinal tolerability

Biogen Grows Presence in China with the Approval of TECFIDERA® (dimethyl fumarate) for the Treatment of Relapsing Multiple Sclerosis

TECFIDERA was approved under the National Medical Products Administration priority review process evaluating therapies with urgent clinical needs More than 500,000 individuals worldwide living with multiple sclerosis (MS) have been treated with TECFIDERA, which has a well-established safety and